Related references
Note: Only part of the references are listed.Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
E. Massarelli et al.
ANNALS OF ONCOLOGY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies
Francesca Pezzuto et al.
ONCOLOGY (2015)
Targeting angiogenesis in head and neck cancer
Maria Vassilakopoulou et al.
ORAL ONCOLOGY (2015)
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno et al.
ORAL ONCOLOGY (2015)
Molecular Biology and Immunology of Head and Neck Cancer
Theresa Guo et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Immunity in Head and Neck Cancer
Jonathan D. Schoenfeld
CANCER IMMUNOLOGY RESEARCH (2015)
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
A. Jimeno et al.
ANNALS OF ONCOLOGY (2015)
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)
V. Gruenwald et al.
ANNALS OF ONCOLOGY (2015)
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim et al.
CLINICAL CANCER RESEARCH (2015)
Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
Ian-James Malm et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T. Y. Seiwert et al.
ANNALS OF ONCOLOGY (2014)
Sequencing the head and neck cancer genome: implications for therapy
Wenyue Sun et al.
ANNALS REPORTS, VOL 1333 (2014)
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
Jean-Pascal H. Machiels et al.
BMC CANCER (2014)
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
M. J. Ward et al.
BRITISH JOURNAL OF CANCER (2014)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
Donald W. Northfelt et al.
CLINICAL CANCER RESEARCH (2014)
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation
Daniel W. Bowles et al.
FUTURE ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis
Cathy Ndiaye et al.
LANCET ONCOLOGY (2014)
ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen
Lori Cory et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Toll-like receptors and cancer, particularly oral squamous cell carcinoma
Alison Mary Rich et al.
FRONTIERS IN IMMUNOLOGY (2014)
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma
Cecilia Nordfors et al.
EUROPEAN JOURNAL OF CANCER (2013)
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
Dong M. Shin et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies
Carlos A. Ramos et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye et al.
ORAL ONCOLOGY (2013)
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
Julie E. Bauman et al.
ORAL ONCOLOGY (2013)
B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
Odey C. Ukpo et al.
HEAD & NECK PATHOLOGY (2013)
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
R. Hitt et al.
ANNALS OF ONCOLOGY (2012)
Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy
Corey Smith et al.
CANCER RESEARCH (2012)
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Jonas A. de Souza et al.
CLINICAL CANCER RESEARCH (2012)
New promising molecular targets in head and neck squamous cell carcinoma
Julie E. Bauman et al.
CURRENT OPINION IN ONCOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Phase 2 Study of Dasatinib in the Treatment of Head and Neck Squamous Cell Carcinoma
Heather D. Brooks et al.
CANCER (2011)
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma
Tatiana Salles de Souza Malaspina et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
Young-Ah Cho et al.
ORAL ONCOLOGY (2011)
Immune Suppression in Head and Neck Cancers: A Review
Anaelle Duray et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
Stephen K. Williamson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Jean-Pascal H. Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma
Dominik Pretscher et al.
BMC CANCER (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Toll-like receptor modulation in head and neck cancer
Ralph Pries et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2008)
Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience
Sabine Roithmaier et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adoptive T cell therapy for cancer in the clinic
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler et al.
NATURE MEDICINE (2007)
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma
Johan W. Molling et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes
P Comoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
X León et al.
CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytokines in cancer pathogenesis and cancer therapy
G Dranoff
NATURE REVIEWS CANCER (2004)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma
K Devaraj et al.
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE (2003)
Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features
JP Rodrigo et al.
ORAL ONCOLOGY (2002)
Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions
H Nagatsuka et al.
ORAL ONCOLOGY (2001)
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
F Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients:: Preliminary study
T Crombet et al.
HYBRIDOMA (2001)
STAT signaling in head and neck cancer
JI Song et al.
ONCOGENE (2000)
The role of STATs in transcriptional control and their impact on cellular function
J Bromberg et al.
ONCOGENE (2000)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
